LncRNA OIP5-AS1 Modulates the Proliferation and Apoptosis of Jurkat Cells by Sponging MiR-181c-5p to Regulate IL-7 Expression in Myasthenia Gravis

Overview

Journal PeerJ

Specialties Biology
Environmental Health
General Medicine

Date 2022 May 23

PMID 35602889

Authors

Xu Wang

Huixue Zhang

Xiaoyu Lu

Shuang Li

Xiaotong Kong

Li Liu

Lifang Li

Si Xu

Tianfeng Wang

Jianjian Wang

Lihua Wang

Affiliations

Soon will be listed here.

Abstract

Background: Myasthenia gravis (MG) is an antibody-mediated autoimmune disease. In recent years, accumulating evidence has indicated that long non-coding RNAs (lncRNAs) can function as competing endogenous RNAs (ceRNAs), contributing to the progression of various autoimmune diseases. Nevertheless, the regulatory roles of ceRNAs in MG pathogenesis remain unclear. In this study, we aimed to elucidate the role of lncRNA OIP5-AS1 as a ceRNA associated with MG progression.

Methods: Real-time PCR was used to detect OIP5-AS1 levels in peripheral blood mononuclear cells (PBMCs) from patients with MG. Luciferase reporter assays were performed to validate the relationship between OIP5-AS1 and miR-181c-5p. CCK-8 and flow cytometry were performed to test the proliferation and apoptotic abilities of OIP5-AS1 in Jurkat cells. Furthermore, real-time PCR and Western blot assays were performed to explore the interactions between OIP5-AS1, miR-181c-5p, and IL-7.

Results: The expression of OIP5-AS1 was up-regulated in patients with MG. Luciferase reporter assay indicated that OIP5-AS1 targeted the miR-181c-5p. Functional assays showed that OIP5-AS1 suppressed Jurkat cell apoptosis and promoted cell proliferation by sponging miR-181c-5p. Mechanistically, knockdown of OIP5-AS1 inhibited IL-7 expression at both the mRNA and protein levels in Jurkat cells, whereas the miR-181c-5p inhibitor blocked the reduction of IL-7 expression induced by OIP5-AS1 suppression.

Conclusions: We confirmed that OIP5-AS1 serves as an endogenous sponge for miR-181c-5p to regulate the expression of IL-7. Our findings provide novel insights into MG processes and suggests potential therapeutic targets for patients with MG.

Citing Articles

Advances in the genetics of myasthenia gravis: insights from cutting-edge neuroscience research.

Yixian Z, Hai W, Xiuying L, Jichun Y Front Med (Lausanne). 2025; 11():1508422.

PMID: 39845831 PMC: 11753242. DOI: 10.3389/fmed.2024.1508422.

Non-Coding RNAs in Myasthenia Gravis: From Immune Regulation to Personalized Medicine.

Iacomino N, Tarasco M, Berni A, Ronchi J, Mantegazza R, Cavalcante P Cells. 2024; 13(18.

PMID: 39329732 PMC: 11430632. DOI: 10.3390/cells13181550.

Non-coding RNA and its network in the pathogenesis of Myasthenia Gravis.

Wang F, Mei X, Yang Y, Zhang H, Li Z, Zhu L Front Mol Biosci. 2024; 11:1388476.

PMID: 39318549 PMC: 11420011. DOI: 10.3389/fmolb.2024.1388476.

The intricate dance of non-coding RNAs in myasthenia gravis pathogenesis and treatment.

Wang B, Zhu Y, Liu D, Hu C, Zhu R Front Immunol. 2024; 15:1342213.

PMID: 38605954 PMC: 11007667. DOI: 10.3389/fimmu.2024.1342213.

Dysregulated Long Non-coding RNAs in Myasthenia Gravis- A Mini-Review.

Sun L, Ye X, Wang L, Yu J, Wu Y, Hua Y Curr Mol Med. 2024; 25(1):2-12.

PMID: 38192147 DOI: 10.2174/0115665240281531231228051037.

References

Tay Y, Rinn J, Pandolfi P . The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014; 505(7483):344-52. PMC: 4113481. DOI: 10.1038/nature12986. View

Wang J, Tang Q, Lu L, Luo Z, Li W, Lu Y . LncRNA OIP5-AS1 interacts with miR-363-3p to contribute to hepatocellular carcinoma progression through up-regulation of SOX4. Gene Ther. 2020; 27(10-11):495-504. DOI: 10.1038/s41434-020-0123-2. View

Vincent A, Palace J, Hilton-Jones D . Myasthenia gravis. Lancet. 2001; 357(9274):2122-8. DOI: 10.1016/S0140-6736(00)05186-2. View

Gilhus N . Myasthenia Gravis. N Engl J Med. 2016; 375(26):2570-2581. DOI: 10.1056/NEJMra1602678. View

Romi F, Gilhus N, Aarli J . Myasthenia gravis: clinical, immunological, and therapeutic advances. Acta Neurol Scand. 2005; 111(2):134-41. DOI: 10.1111/j.1600-0404.2005.00374.x. View

Chen Y, Satpathy A, Chang H . Gene regulation in the immune system by long noncoding RNAs. Nat Immunol. 2017; 18(9):962-972. PMC: 9830650. DOI: 10.1038/ni.3771. View

Cebi M, Durmus H, Aysal F, Ozkan B, Gul G, Cakar A . CD4 T Cells of Myasthenia Gravis Patients Are Characterized by Increased IL-21, IL-4, and IL-17A Productions and Higher Presence of PD-1 and ICOS. Front Immunol. 2020; 11:809. PMC: 7248174. DOI: 10.3389/fimmu.2020.00809. View

Liu R, Li Y, Zhou H, Wang H, Liu D, Wang H . OIP5-AS1 facilitates Th17 differentiation and EAE severity by targeting miR-140-5p to regulate RhoA/ROCK2 signaling pathway. Life Sci. 2021; :119108. DOI: 10.1016/j.lfs.2021.119108. View

Gilhus N, Tzartos S, Evoli A, Palace J, Burns T, Verschuuren J . Myasthenia gravis. Nat Rev Dis Primers. 2019; 5(1):30. DOI: 10.1038/s41572-019-0079-y. View

10.

Batista P, Chang H . Long noncoding RNAs: cellular address codes in development and disease. Cell. 2013; 152(6):1298-307. PMC: 3651923. DOI: 10.1016/j.cell.2013.02.012. View

11.

Riviere E, Pascaud J, Virone A, Dupre A, Ly B, Paoletti A . Interleukin-7/Interferon Axis Drives T Cell and Salivary Gland Epithelial Cell Interactions in Sjögren's Syndrome. Arthritis Rheumatol. 2020; 73(4):631-640. DOI: 10.1002/art.41558. View

12.

Fatica A, Bozzoni I . Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet. 2013; 15(1):7-21. DOI: 10.1038/nrg3606. View

13.

Luo M, Liu X, Meng H, Xu L, Li Y, Li Z . IFNA-AS1 regulates CD4 T cell activation in myasthenia gravis though HLA-DRB1. Clin Immunol. 2017; 183:121-131. DOI: 10.1016/j.clim.2017.08.008. View

14.

Dai J, Xu L, Hu X, Han G, Jiang H, Sun H . Long noncoding RNA OIP5-AS1 accelerates CDK14 expression to promote osteosarcoma tumorigenesis via targeting miR-223. Biomed Pharmacother. 2018; 106:1441-1447. DOI: 10.1016/j.biopha.2018.07.109. View

15.

Bi X, Guo X, Mo B, Wang M, Luo X, Chen Y . LncRNA PICSAR promotes cell proliferation, migration and invasion of fibroblast-like synoviocytes by sponging miRNA-4701-5p in rheumatoid arthritis. EBioMedicine. 2019; 50:408-420. PMC: 6921299. DOI: 10.1016/j.ebiom.2019.11.024. View

16.

Seo Y, Im S, Namkoong H, Kim S, Choi Y, Kang M . Crucial roles of interleukin-7 in the development of T follicular helper cells and in the induction of humoral immunity. J Virol. 2014; 88(16):8998-9009. PMC: 4136280. DOI: 10.1128/JVI.00534-14. View

17.

Mantegazza R, Bernasconi P, Cavalcante P . Myasthenia gravis: from autoantibodies to therapy. Curr Opin Neurol. 2018; 31(5):517-525. DOI: 10.1097/WCO.0000000000000596. View

18.

Cheng Z, Qiu S, Jiang L, Zhang A, Bao W, Liu P . MiR-320a is downregulated in patients with myasthenia gravis and modulates inflammatory cytokines production by targeting mitogen-activated protein kinase 1. J Clin Immunol. 2012; 33(3):567-76. DOI: 10.1007/s10875-012-9834-5. View

19.

Cortes-Vicente E, Gallardo E, Martinez M, Diaz-Manera J, Querol L, Rojas-Garcia R . Clinical Characteristics of Patients With Double-Seronegative Myasthenia Gravis and Antibodies to Cortactin. JAMA Neurol. 2016; 73(9):1099-104. DOI: 10.1001/jamaneurol.2016.2032. View

20.

Niu L, Jiang J, Yin Y, Hu B . LncRNA XLOC_003810 modulates thymic Th17/Treg balance in myasthenia gravis with thymoma. Clin Exp Pharmacol Physiol. 2020; 47(6):989-996. DOI: 10.1111/1440-1681.13280. View